Search research articles
Contact Us
Filters
Showing results (251-260 of 274) with videos related to
Page
of 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy
Michelle D Winthrop, Sally J DeNardo, Huguette Albrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 1998
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
G L DeNardo, S J DeNardo, D S Goldstein, et al.
Cancer
|
February 1, 1994
The biologic window for chimeric L6 radioimmunotherapy
S J DeNardo, G R Mirick, L A Kroger, et al.
Cancer
|
December 24, 1997
Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2
G L DeNardo, D L Kukis, S J DeNardo, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology
|
January 1, 1991
Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy
S J DeNardo, L F O'Grady, D J Macey, et al.
Radiology
|
April 1, 1988
Breast cancer imaging with In-111 human IgM monoclonal antibodies: preliminary studies
K P Ryan, R O Dillman, S J DeNardo, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement
|
January 1, 1988
Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies
S J DeNardo, G L DeNardo, L F O'Grady, et al.
Cancer Research
|
December 1, 1995
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression
S J DeNardo, P H Gumerlock, M D Winthrop, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 1998
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts
G L DeNardo, L A Kroger, C F Meares, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 20, 1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts
S J DeNardo, D L Kukis, L A Miers, et al.
Page
of 28
Search research articles
Search
Showing results (251-260 of 274) with videos related to
Sort By:
Page
of 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy
Michelle D Winthrop, Sally J DeNardo, Huguette Albrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 21, 1998
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
G L DeNardo, S J DeNardo, D S Goldstein, et al.
Cancer
|
February 1, 1994
The biologic window for chimeric L6 radioimmunotherapy
S J DeNardo, G R Mirick, L A Kroger, et al.
Cancer
|
December 24, 1997
Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2
G L DeNardo, D L Kukis, S J DeNardo, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology
|
January 1, 1991
Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy
S J DeNardo, L F O'Grady, D J Macey, et al.
Radiology
|
April 1, 1988
Breast cancer imaging with In-111 human IgM monoclonal antibodies: preliminary studies
K P Ryan, R O Dillman, S J DeNardo, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement
|
January 1, 1988
Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies
S J DeNardo, G L DeNardo, L F O'Grady, et al.
Cancer Research
|
December 1, 1995
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression
S J DeNardo, P H Gumerlock, M D Winthrop, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 1998
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts
G L DeNardo, L A Kroger, C F Meares, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 20, 1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts
S J DeNardo, D L Kukis, L A Miers, et al.
Page
of 28